Smoking cessation and harm reduction: a systematic overview of ongoing, randomized controlled trials
2024

Overview of Ongoing Smoking Cessation Trials

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): Derissen Mara, Scheliga Sebastian, Clemens Benjamin, Leiding Delia, Kröger Knut, Böhner Hinrich, Habel Ute

Primary Institution: RWTH Aachen University

Hypothesis

What are the ongoing randomized controlled trials focusing on smoking cessation and harm reduction?

Conclusion

There is a critical need for more RCTs involving electronic nicotine delivery systems and tailored psychotherapeutic interventions.

Supporting Evidence

  • The review identified 30 ongoing RCTs, with a majority located in North America.
  • A significant number of trials focus on socioeconomically disadvantaged or uninsured populations.
  • Nicotine replacement therapy or smoking cessation medication is consistently used across trials.
  • Psychotherapeutic interventions are employed in 22 trials, with motivational interviewing being the most common method.
  • Only four trials utilize electronic nicotine delivery systems as a harm reduction strategy.
  • The lack of standardized reporting in trial registries was a significant barrier to synthesizing and categorizing information.

Takeaway

This study looked at 30 ongoing trials to help people stop smoking and found that many focus on helping those who are less advantaged, but not enough on cancer survivors.

Methodology

A systematic search was conducted on the International Clinical Trials Registry Platform to identify ongoing RCTs focusing on smoking cessation and harm reduction.

Potential Biases

The review did not conduct a risk of bias assessment of the ongoing RCTs.

Limitations

The review only included ongoing RCTs following German treatment guidelines, potentially limiting the analysis to trials reflecting the most current knowledge.

Participant Demographics

The trials primarily included adults who smoke, with a focus on socioeconomically disadvantaged populations and some targeting specific high-risk groups.

Digital Object Identifier (DOI)

10.1186/s12888-024-06342-6

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication